Impact of assessment and treatment of neuropathic pain in patients with chronic diabetic neuropathy assisted in a diabetes reference service Carolina Ritzmann, Lucia Henriques Alves da Silva * , Rosane Kupfer From 20th Brazilian Diabetes Society Congress Porto Alegre, Brazil. 11-18 November 2015 Background Diabetic neuropathy is one of the chronic complications of hyperglycemia, which characterizes Diabetes Mellitus. As a result of an indolent course, the absence of signs and symptoms and nonspecific manifestations, it can remain undiagnosed for a long time. One of the clinical presentations is the presence of neuropathic symptoms, such as pain, cramps or paresthesia, which can compromise the quality of life.
Objective
The objective of this study was to demonstrate that the pharmacological treatment of neuropathic pain can promote a significant symptomatic improvement assessed by validated scores and that the establishment of a support center in neuropathy constitutes an important measure in the context of multidisciplinary care of the diabetic patient.
Materials and methods
53 patients were recruited with a mean age of 58 yrs., similar gender distribution (50.9% male and 49.1% female), mostly with type 2 Diabetes Mellitus (83%), average diagnosis time of 18 yrs. and median time for neuropathic symptoms of 2 yrs.
Results
At the first visit, subjects had pain intensity classified as moderate by the Analog Pain Scale, intensity of neuropathic symptoms classified as severe (56.6%) and neuropathic disability rated as moderate to severe impairment (41.5%). Following the prescription of specific pharmacological treatment, 91.6% of patients reported maintenance or improvement of symptoms and only 2.8% reported worsening. It was observed significant improvement in Neuropathic Symptoms Score (p=0.0006) and Analogic Pain * Correspondence: luciahenriques@ig.com.br Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione, Rio de Janeiro, Brazil Figure 1 Baseline characteristics of the patients. # values expressed in relative frequency; Analogic Pain Scale: 0-2: mild; 3-7 moderate; 8-10: severe; Neuropathic Symptoms Score: 1-4: mild; 5-6 moderate; 7-10: severe; Neuropathic Disability Score 3-5: mild; 6-8: moderate; 9-10: severe; Uncooperative patients: patients in whose Achilles reflex couldn't be assessed; No information: information not find at the records. Scale (p <0.0001), especially in type 2 diabetic group. There was no change in Neuropathic Disability Score.
Conclusion
This study demonstrated that the existence of a support center for assessment and treatment of painful diabetic neuropathy in a Diabetes reference service allows early diagnosis and intervention in neuropathic symptoms in an effective way. Figure 2 Comparison between clinical parameters before and after pharmacologic treatment of pain. *statistically significant Pvalue (< 0.05); # values expressed in relative frequency; Analogic Pain Scale: 0-2: mild; 3-7 moderate; 8-10: severe; Neuropathic Symptoms Score: 1-4: mild; 5-6 moderate; 7-10: severe; Neuropathic Disability Score 3-5: mild; 6-8: moderate; 9-10: severe; Uncooperative patients: patients in whose Achilles reflex couldn't be assessed; No information: information not find at the records
